DSpace at RU >

Search Results

Results 1-19 of 19.

Item hits:

Full Text	Issue Date	Title	Author(s)
	2011	TRIB3 protein denotes a good prognosis in breast cancer patients and is associated with hypoxia sensitivity	Wennemers, M.; Bussink, J.; Grebenchtchikov, N.J.; Sweep, F.C.; Span, P.N.
	2010	Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer.	Seiz, L.; Kotzsch, M.; Grebenchtchikov, N.J.; Geurts-Moespot, A.; Fuessel, S.; Goettig, P.; Gkazepis, A.; Wirth, M.P.; Schmitt, M.; Lossnitzer, A.; Sweep, F.C.; Magdolen, V.
	2010	Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells.	Gratio, V.; Beaufort, N.; Seiz, L.; Maier, J.; Virca, G.D.; Debela, M.; Grebenchtchikov, N.J.; Magdolen, V.; Darmoul, D.
	2010	Activation of human pro-urokinase by unrelated proteases secreted by Pseudomonas aeruginosa.	Beaufort, N.; Seweryn, P.; Bentzmann, S. de; Tang, A.; Kellermann, J.; Grebenchtchikov, N.J.; Schmitt, M.; Sommerhoff, C.P.; Pidard, D.; Magdolen, V.
	2010	Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders.	Kroot, J.J.C.; Laarakkers, J.M.M.; Geurts-Moespot, A.; Grebenchtchikov, N.J.; Pickkers, P.; Ede, A.E. van; Peters, H.P.E.; Dongen-Lases, E. van; Wetzels, J.F.M.; Sweep, F.C.; Tjalsma, H.; Swinkels, D.W.
	2009	High-sensitive radioimmunoassay for human serum hepcidin.	Grebenchtchikov, N.J.; Geurts-Moespot, A.; Kroot, J.J.C.; Heijer, M. den; Tjalsma, H.; Swinkels, D.W.; Sweep, C.G.J.
	2007	Identification and characterization of multiple species of tenascin-X in human serum.	Egging, D.; Peeters, A.C.T.; Grebenchtchikov, N.I.; Geurts-Moespot, A.; Sweep, C.G.J.; Heijer, M. den; Schalkwijk, J.
	2007	Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis.	Emonts, M.; Sweep, C.G.J.; Grebenchtchikov, N.I.; Geurts-Moespot, A.; Knaup, M.; Chanson, A.L.; Erard, V.; Renner, P.; Hermans, P.W.M.; Hazelzet, J.A.; Calandra, T.
	2005	Concerns about mammaglobin assays.	Span, P.N.; Grebenchtchikov, N.I.; Geurts-Moespot, A.; Sweep, C.G.J.
	2005	Development of a sensitive ELISA for the quantification of human tumour necrosis factor-alpha using 4 polyclonal antibodies.	Grebenchtchikov, N.I.; Ven-Jongekrijg, J. van der; Pesman, G.J.; Geurts-Moespot, A.; Meer, J.W.M. van der; Sweep, C.G.J.
	2005	Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.	Grebenchtchikov, N.I.; Maguire, T.M.; Riisbro, R.; Geurts-Moespot, A.; O'Donovan, N.; Schmitt, M.; McGreal, G.; McDermott, E.; O'Higgins, N.; Brunner, N.; Sweep, C.G.J.; Duffy, M.J.
	2004	Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer.	Dorssers, L.C.; Grebenchtchikov, N.J.; Brinkman, A.B.; Look, M.P.; Klijn, J.G.M.; Geurts-Moespot, A.; Span, P.N.; Foekens, J.A.; Sweep, C.G.J.
	2004	Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue.	Grebenchtchikov, N.J.; Brinkman, A.B.; Broekhoven, S.P. van; Jong, D. de; Geurts-Moespot, A.; Span, P.N.; Peters, H.A.; Portengen, H.; Foekens, J.A.; Sweep, C.G.J.; Dorssers, L.C.
	2004	The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.	Manders, P.; Tjan-Heijnen, V.C.; Span, P.N.; Grebenchtchikov, N.J.; Geurts-Moespot, A.; Tienoven, D.T. van; Beex, L.V.A.M.; Sweep, C.G.J.
	2004	Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.	Manders, P.; Tjan-Heijnen, V.C.; Span, P.N.; Grebenchtchikov, N.J.; Foekens, J.A.; Beex, L.V.A.M.; Sweep, C.G.J.
	2004	The prognostic value of BCAR1 in patients with primary breast cancer.	Dorssers, L.C.; Grebenchtchikov, N.J.; Brinkman, A.B.; Look, M.P.; Broekhoven, S.P. van; Jong, D. de; Peters, H.A.; Portengen, H.; Meijer-van Gelder, M.E.; Klijn, J.G.M.; Tienoven, D.T. van; Geurts-Moespot, A.; Span, P.N.; Foekens, J.A.; Sweep, C.G.J.
	2004	Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.	Manders, P.; Tjan-Heijnen, V.C.; Span, P.N.; Grebenchtchikov, N.J.; Geurts-Moespot, A.; Tienoven, D.T. van; Beex, L.V.A.M.; Sweep, C.G.J.
	1997	A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols	Grebenchtchikov, N.I.; Geurts-Moespot, A.; Witte, J.H. de; Heuvel, J.J.T.M.; Leake, R.; Sweep, C.G.J.; Benraad, T.J.
	1996	Quality control in quantitation of components of the plasminogen activator system in tumour extracts	Benraad, T.J.; Geurts-Moespot, A.; Grebenchtchikov, N.I.; Witte, J.H. de; Heuvel, J.J.T.M.; Sweep, C.G.J.

1